Mechanism of Genome Editing Tools and Their Application on Genetic Inheritance Disorders

Abstract

In the fields of medicine and bioscience, gene editing is increasingly recognized as a promising therapeutic approach for treating pathogenic variants in humans and other living organisms. With advancements in technology and knowledge, it is now understood that most genetic defects are caused by single-base pair variants. The ability to substitute genes using genome editing tools enables scientists and doctors to cure genetic diseases and disorders. Starting with CRISPR (clustered regularly interspaced short palindromic repeats)/Cas, the technology has evolved to become more efficient and safer, leading to the development of base and prime editors. Furthermore, various approaches are used to treat genetic disorders such as hemophilia, cystic fibrosis, and Duchenne muscular dystrophy. As previously mentioned, most genetic defects leading to specific diseases are caused by single-base pair variants, which can occur at many locations in corresponding gene, potentially causing the same disease. This means that, even when using the same genome editing tool, results in terms of editing efficiency or treatment effectiveness may differ. Therefore, different approaches may need to be applied to different types of diseases. Prevalently, due to the safety of adeno-associated virus (AAV) vectors in gene therapy, most clinical trials of gene therapy are based on AAV delivery methods. However, despite their safety and nonintegration into the host genome, their limitations, such as confined capacity, dosage-dependent viral toxicity, and immunogenicity, necessitate the development of new approaches to enhance treatment effects. This review provides the structure and function of each CRISPR-based gene editing tool and focuses on introducing new approaches in gene therapy associated with improving treatment efficiency.

Keywords

gene therapy / hemophilia / cystic fibrosis / Duchenne muscular dystrophy / CRISPR / base editor / prime editor

References

[1] Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature 2016; 533(7603) 420-424

[2] Anzalone AV, Randolph PB, Davis JR, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature 2019; 576(7785) 149-157

[3] Rubinstein YR, Groft SC, Bartek R, et al. Creating a global rare disease patient registry linked to a rare diseases biorepository database: rare disease-HUB (RD-HUB). Contemp Clin Trials 2010; 31(05) 394-404

[4] Verdera HC, Kuranda K, Mingozzi F. AAV vector immunogenicity in humans: a long journey to successful gene transfer. Mol Ther 2020; 28(03) 723-746

[5] Calcedo R, Vandenberghe LH, Gao G, Lin J, Wilson JM. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. J Infect Dis 2009; 199(03) 381-390

[6] Kishimoto TK, Samulski RJ. Addressing high dose AAV toxicity - 'one and done' or 'slower and lower'?. Expert Opin Biol Ther 2022; 22(09) 1067-1071

[7] Mojica FJ, Díez-Villaseñor C, Soria E, Juez G. Biological significance of a family of regularly spaced repeats in the genomes of archaea, bacteria and mitochondria. Mol Microbiol 2000; 36(01) 244-246

[8] Lim Y, Bak SY, Sung K, et al. Structural roles of guide RNAs in the nuclease activity of Cas9 endonuclease. Nat Commun 2016; 7: 13350

[9] Gleditzsch D, Pausch P, Müller-Esparza H, et al. PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures. RNA Biol 2019; 16(04) 504-517

[10] Anzalone AV, Koblan LW, Liu DR. Genome editing with CRISPR-Cas nucleases, base editors, transposases and prime editors. Nat Biotechnol 2020; 38(07) 824-844

[11] Janik E, Niemcewicz M, Ceremuga M, Krzowski L, Saluk-Bijak J, Bijak M. Various aspects of a gene editing system—CRISPR-Cas9. Int J Mol Sci 2020; 21(24) 9604

[12] Eid A, Alshareef S, Mahfouz MM. CRISPR base editors: genome editing without double-stranded breaks. Biochem J 2018; 475(11) 1955-1964

[13] Molla KA, Yang Y. CRISPR/Cas-mediated base editing: technical considerations and practical applications. Trends Biotechnol 2019; 37(10) 1121-1142

[14] Shen B, Zhang W, Zhang J, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods 2014; 11(04) 399-402

[15] Gu S, Bodai Z, Cowan QT, Komor AC. Base editor: expanding the types of DNA damage products harnessed for genome editing. Gend Genome Ed 2021; 100005

[16] Evanoff M, Komor AC. Base editors: modular tools for the introduction of point mutations in living cells. Emerg Top Life Sci 2019; 3(05) 483-491

[17] Rees HA, Liu DR. Base editing: precision chemistry on the genome and transcriptome of living cells. Nat Rev Genet 2018; 19(12) 770-788

[18] Liu Y, Kao HI, Bambara RA. Flap endonuclease 1: a central component of DNA metabolism. Annu Rev Biochem 2004; 73: 589-615

[19] Keijzers G, Bohr VA, Rasmussen LJ. Human exonuclease 1 (EXO1) activity characterization and its function on flap structures. Biosci Rep 2015; 35(03) e00206

[20] Komor AC, Zhao KT, Packer MS, et al. Improved base excision repair inhibition and bacteriophage Mu Gam protein yields C:G-to-T:A base editors with higher efficiency and product purity. Sci Adv 2017; 3 (08) eaao4774

[21] Landrum MJ, Lee JM, Benson M, et al. ClinVar: public archive of interpretations of clinically relevant variants. Nucleic Acids Res 2016; 44(D1): D862-D868

[22] Lassalle F, Jourdy Y, Jouan L, et al. The challenge of genetically unresolved haemophilia A patients: interest of the combination of whole F8 gene sequencing and functional assays. Haemophilia 2020; 26(06) 1056-1063

[23] Carcao MD. The diagnosis and management of congenital hemophilia. Semin Thromb Hemost 2012; 38(07) 727-734

[24] White II GC, Kempton CL, Grimsley A, Nielsen B, Roberts HR. Cellular immune responses in hemophilia: why do inhibitors develop in some, but not all hemophiliacs?. J Thromb Haemost 2005; 3(08) 1676-1681

[25] Kitazawa T, Shima M. Emicizumab, a humanized bispecific antibody to coagulation factors IXa and X with a factor VIIIa-cofactor activity. Int J Hematol 2020; 111(01) 20-30

[26] Franchini M, Zaffanello M, Lippi G. The use of desmopressin in mild hemophilia A. Blood Coagul Fibrinolysis 2010; 21(07) 615-619

[27] Franchini M, Mannucci PM. The more recent history of hemophilia treatment. Semin Thromb Hemost 2022; 48(08) 904-910

[28] Ohmori T. Advances in gene therapy for hemophilia: basis, current status, and future perspectives. Int J Hematol 2020; 111(01) 31-41

[29] Nathwani AC, Tuddenham EG, Rangarajan S, et al. Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 2011; 365(25) 2357-2365

[30] Manno CS, Pierce GF, Arruda VR, et al. Successful transduction of liver in hemophilia by AAV-factor IX and limitations imposed by the host immune response. Nat Med 2006; 12(03) 342-347

[31] Jiang H, Couto LB, Patarroyo-White S, et al. Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy. Blood 2006; 108(10) 3321-3328

[32] Ohmori T, Nagao Y, Mizukami H, et al. CRISPR/Cas9-mediated genome editing via postnatal administration of AAV vector cures haemophilia B mice. Sci Rep 2017; 7(01) 4159

[33] Luo S, Li Z, Dai X, et al. CRISPR/Cas9-mediated in vivo genetic correction in a mouse model of hemophilia A. Front Cell Dev Biol 2021; 9: 672564

[34] Morishige S, Mizuno S, Ozawa H, et al. CRISPR/Cas9-mediated gene correction in hemophilia B patient-derived iPSCs. Int J Hematol 2020; 111(02) 225-233

[35] Dinh LV, Fine EJ, Ameri A, et al. Specific correction of the intron-22 inverted factor VIII gene in autologous blood outgrowth endothelial cells from patients with severe hemophilia A. Blood 2020; 136(01) 30-31

[36] Wang M, Sun Z, Zou Z, et al. Efficient targeted integration into the bovine Rosa26 locus using TALENs. Sci Rep 2018; 8(01) 10385

[37] Jayandharan GR, Zhong L, Sack BK, et al. Optimized adeno-associated virus (AAV)-protein phosphatase-5 helper viruses for efficient liver transduction by single-stranded AAV vectors: therapeutic expression of factor IX at reduced vector doses. Hum Gene Ther 2010; 21(03) 271-283

[38] Sarangi P, Kumar N, Sambasivan R, et al. AAV mediated genome engineering with a bypass coagulation factor alleviates the bleeding phenotype in a murine model of hemophilia B. Thromb Res 2024; 238: 151-160

[39] Meng N, Grimm D. Membrane-destabilizing ionizable phospholipids: novel components for organ-selective mRNA delivery and CRISPR-Cas gene editing. Signal Transduct Target Ther 2021; 6(01) 206

[40] Han JP, Kim M, Choi BS, et al. In vivo delivery of CRISPR-Cas9 using lipid nanoparticles enables antithrombin gene editing for sustainable hemophilia A and B therapy. Sci Adv 2022; 8 (03) eabj6901

[41] Nishimasu H, Shi X, Ishiguro S, et al. Engineered CRISPR-Cas9 nuclease with expanded targeting space. Science 2018; 361(6408) 1259-1262

[42] Nishida K, Arazoe T, Yachie N, et al. Targeted nucleotide editing using hybrid prokaryotic and vertebrate adaptive immune systems. Science 2016; 353 (6305) aaf8729

[43] Truong D-JJ, Kühner K, Kühn R, et al. Development of an intein-mediated split-Cas9 system for gene therapy. Nucleic Acids Res 2015; 43(13) 6450-6458

[44] Hiramoto T, Kashiwakura Y, Hayakawa M, et al. PAM-flexible Cas9-mediated base editing of a hemophilia B mutation in induced pluripotent stem cells. Commun Med (Lond) 2023; 3(01) 56

[45] Di Scipio RG, Kurachi K, Davie EW. Activation of human factor IX (Christmas factor). J Clin Invest 1978; 61(06) 1528-1538

[46] Walsh DP, Murphy RD, Panarella A, et al. Bioinspired star-shaped poly(l-lysine) polypeptides: efficient polymeric nanocarriers for the delivery of DNA to mesenchymal stem cells. Mol Pharm 2018; 15(05) 1878-1891

[47] Rong L, Chen D, Huang X, Sun L. Delivery of Cas9-guided ABE8e into stem cells using poly(l-lysine) polypeptides for correction of the hemophilia-associated FIX missense mutation. Biochem Biophys Res Commun 2022; 628: 49-56

[48] Giangrande P. Haemophilia B: Christmas disease. Expert Opin Pharmacother 2005; 6(09) 1517-1524

[49] Bulcaen M, Carlon MS. Genetic surgery for a cystic fibrosis-causing splicing mutation. Mol Ther Methods Clin Dev 2024; 32(01) 101177

[50] Amaral MD, Kunzelmann K. Molecular targeting of CFTR as a therapeutic approach to cystic fibrosis. Trends Pharmacol Sci 2007; 28(07) 334-341

[51] Miquéias L.-P. CFTR modulators: The changing face of cystic fibrosis in the era of precision medicine. Front Pharmacol 2020; Feb 21: 10: 1662

[52] Fischer AC, Beck SE, Smith CI, et al. Successful transgene expression with serial doses of aerosolized rAAV2 vectors in rhesus macaques. Mol Ther 2003; 8(06) 918-926

[53] Fischer AC, Smith CI, Cebotaru L, et al. Expression of a truncated cystic fibrosis transmembrane conductance regulator with an AAV5-pseudotyped vector in primates. Mol Ther 2007; 15(04) 756-763

[54] Moss RB, Milla C, Colombo J, et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. Hum Gene Ther 2007; 18(08) 726-732

[55] Moss RB, Rodman D, Spencer LT, et al. Repeated adeno-associated virus serotype 2 aerosol-mediated cystic fibrosis transmembrane regulator gene transfer to the lungs of patients with cystic fibrosis: a multicenter, double-blind, placebo-controlled trial. Chest 2004; 125(02) 509-521

[56] Zhang L, Button B, Gabriel SE, et al. CFTR delivery to 25% of surface epithelial cells restores normal rates of mucus transport to human cystic fibrosis airway epithelium. PLoS Biol 2009; 7(07) e1000155

[57] Walker AJ, Graham C, Greenwood M, et al. Molecular and functional correction of a deep intronic splicing mutation in CFTR by CRISPR-Cas9 gene editing. Mol Ther Methods Clin Dev 2023; 31: 101140

[58] Hamosh A, Trapnell BC, Zeitlin PL, et al. Severe deficiency of cystic fibrosis transmembrane conductance regulator messenger RNA carrying nonsense mutations R553X and W1316X in respiratory epithelial cells of patients with cystic fibrosis. J Clin Invest 1991; 88(06) 1880-1885

[59] Matsoukas IG. Commentary: Programmable base editing of A·T to G·C in genomic DNA without DNA cleavage. Front Genet 2018; 9: 21

[60] Zabner J, Karp P, Seiler M, et al. Development of cystic fibrosis and noncystic fibrosis airway cell lines. Am J Physiol Lung Cell Mol Physiol 2003; 284(05) L844-L854

[61] Miller SM, Wang T, Randolph PB, et al. Continuous evolution of SpCas9 variants compatible with non-G PAMs. Nat Biotechnol 2020; 38(04) 471-481

[62] Krishnamurthy S, Traore S, Cooney AL, et al. Functional correction of CFTR mutations in human airway epithelial cells using adenine base editors. Nucleic Acids Res 2021; 49(18) 10558-10572

[63] Kim S, Kim D, Cho SW, Kim J, Kim J-S. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res 2014; 24(06) 1012-1019

[64] Yeh WH, Chiang H, Rees HA, Edge ASB, Liu DR. In vivo base editing of post-mitotic sensory cells. Nat Commun 2018; 9(01) 2184

[65] Palmer D, Ng P. Improved system for helper-dependent adenoviral vector production. Mol Ther 2003; 8(05) 846-852

[66] Cao H, Ouyang H, Grasemann H, et al. Transducing airway basal cells with a helper-dependent adenoviral vector for lung gene therapy. Hum Gene Ther 2018; 29(06) 643-652

[67] Li C, Liu Z, Anderson J, et al. Prime editing-mediated correction of the CFTR W1282X mutation in iPSCs and derived airway epithelial cells. PLoS One 2023; 18(11) e0295009

[68] Duan D, Goemans N, Takeda S, Mercuri E, Aartsma-Rus A. Duchenne muscular dystrophy. Nat Rev Dis Primers 2021; 7(01) 13

[69] Laurent M, Geoffroy M, Pavani G, Guiraud S. CRISPR-based gene therapies: from preclinical to clinical treatments. Cells 2024; 13(10) 800

[70] England SB, Nicholson LVB, Johnson MA, et al. Very mild muscular dystrophy associated with the deletion of 46% of dystrophin. Nature 1990; 343(6254) 180-182

[71] Hoffman EP, Kunkel LM, Angelini C, Clarke A, Johnson M, Harris JB. Improved diagnosis of Becker muscular dystrophy by dystrophin testing. Neurology 1989; 39(08) 1011-1017

[72] Helderman-van den Enden AT, Straathof CS, Aartsma-Rus A, et al. Becker muscular dystrophy patients with deletions around exon 51; a promising outlook for exon skipping therapy in Duchenne patients. Neuromuscul Disord 2010; 20(04) 251-254

[73] Tsoumpra MK, Fukumoto S, Matsumoto T, Takeda S, Wood MJA, Aoki Y. Peptide-conjugate antisense based splice-correction for Duchenne muscular dystrophy and other neuromuscular diseases. EBioMedicine 2019; 45: 630-645

[74] Matsuo M. Antisense oligonucleotide-mediated exon-skipping therapies: precision medicine spreading from Duchenne muscular dystrophy. JMA J 2021; 4(03) 232-240

[75] Duan D. Systemic AAV micro-dystrophin gene therapy for Duchenne muscular dystrophy. Mol Ther 2018; 26(10) 2337-2356

[76] Nelson CE, Hakim CH, Ousterout DG, et al. In vivo genome editing improves muscle function in a mouse model of Duchenne muscular dystrophy. Science 2016; 351(6271) 403-407

[77] Hinderer C, Katz N, Buza EL, et al. Severe toxicity in nonhuman primates and piglets following high-dose intravenous administration of an adeno-associated virus vector expressing human SMN. Hum Gene Ther 2018; 29(03) 285-298

[78] Kornegay JN, Li J, Bogan JR, et al. Widespread muscle expression of an AAV9 human mini-dystrophin vector after intravenous injection in neonatal dystrophin-deficient dogs. Mol Ther 2010; 18(08) 1501-1508

[79] Zhang Y, Li H, Nishiyama T, et al. A humanized knockin mouse model of Duchenne muscular dystrophy and its correction by CRISPR-Cas9 therapeutic gene editing. Mol Ther Nucleic Acids 2022; 29: 525-537

[80] Koblan LW, Doman JL, Wilson C, et al. Improving cytidine and adenine base editors by expression optimization and ancestral reconstruction. Nat Biotechnol 2018; 36(09) 843-846

[81] Oeemig JS, Aranko AS, Djupsjöbacka J, Heinämäki K, Iwaï H. Solution structure of DnaE intein from Nostoc punctiforme: structural basis for the design of a new split intein suitable for site-specific chemical modification. FEBS Lett 2009; 583(09) 1451-1456

[82] Chemello F, Chai AC, Li H, et al. Precise correction of Duchenne muscular dystrophy exon deletion mutations by base and prime editing. Sci Adv 2021; 7 (18) eabg4910

[83] Srivastava A. AAV vectors: are they safe?. Hum Gene Ther 2020; 31(13-14): 697-699

[84] Oren YS, Irony-Tur Sinai M, Golec A, et al. Antisense oligonucleotide-based drug development for cystic fibrosis patients carrying the 3849+10 kb C-to-T splicing mutation. J Cyst Fibros 2021; 20(05) 865-875

[85] Di Gioia S, Trapani A, Castellani S, et al. Nanocomplexes for gene therapy of respiratory diseases: targeting and overcoming the mucus barrier. Pulm Pharmacol Ther 2015; 34: 8-24

[86] Zhao Z, Shang P, Mohanraju P, Geijsen N. Prime editing: advances and therapeutic applications. Trends Biotechnol 2023; 41(08) 1000-1012

[87] Ling X, Xie B, Gao X, et al. Improving the efficiency of precise genome editing with site-specific Cas9-oligonucleotide conjugates. Sci Adv 2020; 6 (15) eaaz0051

[88] Strecker J, Ladha A, Gardner Z, et al. RNA-guided DNA insertion with CRISPR-associated transposases. Science 2019; 365(6448) 48-53

[89] Klompe SE, Vo PLH, Halpin-Healy TS, Sternberg SH. Transposon-encoded CRISPR-Cas systems direct RNA-guided DNA integration. Nature 2019; 571(7764) 219-225

[90] Yang C, Zhou Z, Sun X, et al. PAMless SpRY exhibits a preference for the seed region for efficient targeting. Cell Rep 2024; 43(05) 114225

[91] Huang S, Liao Z, Li X, et al. Developing ABEmax-NG with precise targeting and expanded editing scope to model pathogenic splice site mutations in vivo. iScience 2019; 15: 640-648

RIGHTS & PERMISSIONS

2024 Global Medical Genetics